PathoSeq Bio is a pioneering biotechnology company specializing in next-generation sequencing (NGS) workflows and advanced bioinformatics solutions. We have developed a proprietary hybrid-capture protocol optimized for Oxford Nanopore Technologies’ portable sequencers, enabling pathogen detection anywhere in the world—from public health laboratories and clinical hospitals to resource-limited settings.
Our mission is to make comprehensive infectious disease diagnostics universally accessible. Leveraging a single assay capable of detecting thousands of viral, bacterial, and fungal pathogens, our platform surpasses traditional syndromic panels to cover a wide range of illnesses, including enteric (e.g., cholera, norovirus), respiratory (e.g., SARS-CoV-2, influenza), and febrile (e.g., dengue, malaria) infections.